Lack of clinical therapeutic synergism between cyclophosphamide, adriamycin, and cis-dichlorodiammineplatinum(II) in metastatic human colorectal carcinoma.

Thirty patients with metastatic adenocarcinoma originating in the colon or rectum were treated with a combination of cyclophosphamide, Adriamycin, and cis-dichlorodiammineplatinum(II). Only one partial tumor regression of 12 weeks' duration was observed. Severe nausea and vomiting secondary to chemotherapy were frequently seen. This three-drug regimen, as employed in our study, was not associated with useful clinical activity against human metastatic colorectal cancer.